SCHEMBL21598677

SCHEMBL21598677

NC(=O)c1ccc(Cl)n2ccnc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.42
MALT1 Q9UDY8 1/20 0.39
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
DYRK1B Q9Y463 2/20 0.35
MAP2K1 Q02750 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
PARP1 P09874 3/20 0.35
IRAK4 Q9NWZ3 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
RAB9A P51151 1/20 0.34
CSNK1A1 P48729 1/20 0.33
TYRO3 Q06418 1/20 0.33
ADRA1A P35348 1/20 0.33
MAPKAPK5 Q8IW41 1/20 0.33
NTRK1 P04629 1/20 0.33
PIM1 P11309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19551405 0.80 MKNK1 (0.42) MKNK1MALT1KDM4ESMN1; SMN2DYRK1B
SCHEMBL13281267 0.80 KDM4E (0.41) KDM4ESMN1; SMN2MAP2K1ATML3MBTL1
SCHEMBL21598667 0.78 MKNK1 (0.43) MKNK1MALT1KDM4EDYRK1BMAP2K1
SCHEMBL22490646 0.72 CCNE1 (0.38) ADRA1A
SCHEMBL11337894 0.72 ZAP70 (0.41) NTRK1PIM1ACVR1
SCHEMBL22902470 0.72 CASP1 (0.36) MKNK1MALT1KDM4EDYRK1BMAP2K1
SCHEMBL17742993 0.70 MKNK1 (0.42) MKNK1KDM4ESMN1; SMN2DYRK1BMAP2K1
SCHEMBL10133967 0.69 SSTR4 (0.36) MALT1KDM4ECLK4L3MBTL1
SCHEMBL30326244 0.69 CCNE1 (0.33) L3MBTL1
SCHEMBL1685106 0.69 CCNE1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810609-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-12 EP disclosed
CN-112601747-B Pyrazole derivatives as MALT1 inhibitors 詹森药业有限公司 2023-02-21 CN disclosed
EP-3810609-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2021-04-28 EP disclosed
CN-112601747-A Pyrazole derivatives as MALT1 inhibitors 詹森药业有限公司 2021-04-02 CN disclosed
US-10888550-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-01-12 US disclosed
US-10888550-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-01-12 US disclosed
WO-2019243965-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
WO-2019243965-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10888550-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 MKNK1 415/4885MALT1 1/4885KDM4E 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.